Virios Therapeutics, Inc. has merged with Sealbond Limited’s subsidiary, Pharmagesic, renaming the company Dogwood Therapeutics, Inc., and shifting focus to developing non-opioid pain treatments and antiviral drugs for long-term conditions such as chemotherapy-induced neuropathic pain. The deal includes a reverse stock split and financing arrangements to support research and operations. Dogwood’s new leadership and board members are set to steer the company towards key milestones, with an emphasis on advancing their clinical programs and exploring partnership opportunities.
https://finance.yahoo.com/news/virios-therapeutics-transforms-dogwood-therapeutics-122907415.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.